We found that periodic fasting increases the anti-cancer activity of endocrine agents used to treat hormone receptor-positive breast cancer and delays acquired resistance to them by reducing blood leptin, insulin and insulin-like growth factor 1 (IGF1). Our work supports further clinical studies of fasting as an adjuvant to endocrine agents in breast cancer patients.

Enhancing endocrine therapy activity via fasting cycles: biological rationale and clinical feasibility

Caffa I.;Nencioni A.
2021-01-01

Abstract

We found that periodic fasting increases the anti-cancer activity of endocrine agents used to treat hormone receptor-positive breast cancer and delays acquired resistance to them by reducing blood leptin, insulin and insulin-like growth factor 1 (IGF1). Our work supports further clinical studies of fasting as an adjuvant to endocrine agents in breast cancer patients.
File in questo prodotto:
File Dimensione Formato  
caffa2020_editorial.pdf

accesso chiuso

Descrizione: full article
Tipologia: Documento in versione editoriale
Dimensione 516.51 kB
Formato Adobe PDF
516.51 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/1063447
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact